

HHS Public Access

Author manuscript Circulation. Author manuscript; available in PMC 2019 December 11.

Published in final edited form as: Circulation. 2018 December 11; 138(24): 2858–2859. doi:10.1161/CIRCULATIONAHA.118.034760.

Letter by Russell et al. Regarding Article, "Association Between Early Hyperoxia Exposure After Resuscitation from Cardiac Arrest and Neurological Disability: A Prospective Multi-Center Protocol-Directed Cohort Study"

Derek W. Russell, MD1 and **David R. Janz, MD, MSc**²

¹The Lung Health Center, Department of Medicine, Division of Pulmonary, Allergy, and Critical Care, University of Alabama at Birmingham, Birmingham, AL

²School of Medicine New Orleans, Section of Pulmonary/Critical Care & Allergy/Immunology, Louisiana State University, New Orleans, LA

To the Editor:

We applaud Roberts et al. on their study¹ of the association between hyperoxia exposure and mortality and neurological function in cardiac arrest patients. Although similar findings have been reported^{2, 3} this analysis considerably strengthens the case for hyperoxia-mediated harm in the post-cardiac arrest setting. In contrast to many such studies, it included a prospective data collection design with protocolized arterial blood gas (ABG) measurements allowing for calculation of time-weighted average of PaO₂. However, we feel that the data published in this manuscript is too limited to firmly support two of the authors' conclusions.

The statement by the authors that the "increased risk of poor neurological function appears to begin at 300mmHg" is misleading. In reality, this analysis shows that >300mmHg was the lowest *cutoff associated* with a *statistically significant* risk of poor neurological function. While this may sound like a small difference, it is significant. Because the hyperoxic tail is included in all the cutoffs analyzed, the numerical trend is toward harm in them all. In fact, Figure 3 suggests that perhaps there may be a threshold effect at \sim 250mmHg (as the mean point estimate shifts rightward beginning at this point), but use of this threshold does not show a statistically significant risk. It is premature to conclude, on the basis of these data, that harm from hyperoxia "begins" at any particular point, because this finding is limited by the statistical power of the analysis. In the absence of randomized trials (for which there may never be sufficient equipoise) the causal nature of this association is uncertain; on the other hand it remains unknown whether there is really a "safe" range of supraphysiologic arterial oxygen tension at all, a question which may vary between patient populations^{4, 5}. To mitigate or affirm these concerns, would the authors be able to report point-estimates of risk

Disclosures:

Corresponding Author: Derek W. Russell, MD, Lyons Harrison Research Building Room 321, 700 19th St. S., Birmingham, AL 35294, dwrussell@uabmc.edu.

The authors declare that they have no conflict of interest related to this manuscript.

Russell and Janz Page 2

in the subset of patients that fell in a hyperoxic range below the 300mmHg threshold (perhaps 200–299mmHg)?

We also disagree with the conclusion that providers must frequently measure ABG $PaO₂$ levels to reliably exclude hyperoxia. This assertion is based upon the poor correlation observed (r=0.23) between $SaO₂$ and PaO₂. Hemoglobin saturation and PaO₂ are not measured on the same scale, and indeed, the maximum $SaO₂$ of adult human hemoglobin corresponds, assuming normal homeostatic conditions, to less than $1/6$ the maximum PaO₂ that can be achieved. The absence of a numerical correlation between these two different values is therefore clinically and scientifically meaningless, merely describing the already known sigmoidal, not linear, oxyhemoglobin dissociation curve. Supplemental Figures 1 and 3 appear to show that significant hyperoxia in the presence of a saturation below the high 90s was rare; it seems likely to us that these rare exceptions were patients with poor plethysmographic waveforms, which a bedside provider would readily recognize as an indication to proceed with ABG analysis. Therefore, with the use of clinical judgment, the SpO₂ can still often be used to rule out hyperoxia, avoiding unnecessary phlebotomy and resultant harms.

Acknowledgments

Sources of Funding:

NIH/National Heart Lung and Blood Institute T32HL105346–07 to DWR

References:

- 1. Roberts BW, Kilgannon JH, Hunter BR, Puskarich MA, Pierce L, Donnino M, Leary M, Kline JA, Jones AE, Shapiro NI, Abella BS and Trzeciak S. Association Between Early Hyperoxia Exposure After Resuscitation from Cardiac Arrest and Neurological Disability: A Prospective Multi-Center Protocol-Directed Cohort Study. Circulation. 2018; 137: 2114–2124. [PubMed: 29437118]
- 2. Janz DR, Hollenbeck RD, Pollock JS, McPherson JA and Rice TW. Hyperoxia is associated with increased mortality in patients treated with mild therapeutic hypothermia after sudden cardiac arrest. Crit Care Med. 2012;40:3135–139. [PubMed: 22971589]
- 3. Kilgannon JH, Jones AE, Shapiro NI, Angelos MG, Milcarek B, Hunter K, Parrillo JE, Trzeciak S and Emergency Medicine Shock Research Network I. Association between arterial hyperoxia following resuscitation from cardiac arrest and in-hospital mortality. JAMA. 2010;303:2165–2171. [PubMed: 20516417]
- 4. Russell DW, Janz DR, Emerson WL, May AK, Bernard GR, Zhao Z, Koyama T and Ware LB. Early exposure to hyperoxia and mortality in critically ill patients with severe traumatic injuries. BMC Pulm Med. 2017;17:29. [PubMed: 28158980]
- 5. Girardis M, Busani S, Damiani E, Donati A, Rinaldi L, Marudi A, Morelli A, Antonelli M and Singer M. Effect of Conservative vs Conventional Oxygen Therapy on Mortality Among Patients in an Intensive Care Unit: The Oxygen-ICU Randomized Clinical Trial. JAMA. 2016;316:1583–1589. [PubMed: 27706466]